Abilify Lawsuits Set for Trial this Summer


Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Florida courthouse

The first lawsuit in a large federal case over antipsychotic drug Abilify is scheduled for trial June 18, 2018.

Abilify treats mental disorders such as schizophrenia and bipolar disorder. About 750 lawsuits claim the drug caused compulsive behavior, including compulsive gambling.

The cases are combined in a multidistrict litigation (MDL) in a Florida federal court. The MDL judge this week selected three lawsuits to go to trial. All have trial dates this summer.

Abilify Cases and 2018 Trial Dates:

  • Lyons v. Bristol-Myers Squibb – Jun. 18
  • Viechec v. Bristol-Myers Squibb – Aug. 6
  • Lilly v. Bristol-Myers Squibb – Aug. 27

The lawsuits target both Bristol-Myers Squibb and Japanese drugmaker Otsuka Pharmaceuticals. Otsuka invented Abilify. Bristol-Myers Squibb stopped marketing the drug in 2013.

Lawsuits Blame Abilify for Compulsive Behavior

The lawsuits claim Abilify caused uncontrollable compulsive behavior. People reported losing thousands of dollars through compulsive gambling or spending. Others reported hypersexuality, urges to steal or shoplift, and binge eating.

Did you suffer from compulsive behavior after Abilify use? Get a Free Case Review

The U.S. Food and Drug Administration has tracked Abilify’s association with impulse-control side effects since 2002. The agency’s database showed nearly 500 reports of gambling disorder through the end of 2017.

Abilify’s label did not carry a warning about a compulsive gambling side effect until 2016. People claim the side effect cost them thousands of dollars.  People filed lawsuits to recover money they lost due to the behavior. They also seek expenses for treatment they needed for compulsive behavior.

Lawsuits Chosen for Convenience, Speedy Trials

The MDL judge noted the trials are not “true bellwether” trials. Bellwethers are representative samples of all the lawsuits in an MDL. They serve as test cases for the legal arguments in the MDL. Bellwethers can determine settlements or cause people to drop their cases.

Judge M. Casey Rodgers said in court documents the court chose all three lawsuits for convenience. They were all filed in the same district where the MDL was consolidated. This allows for a speedier trial schedule. All three trials are set for federal court in Pensacola.


6 Cited Research Articles

  1. U.S. District Court, Northern District of Florida. (2018, March 13). Order; In re: Abilify (Aripiprazole) Products Liability Litigation. Retrieved from http://www.pacer.gov
  2. U.S. District Court, Northern District of Florida. (2018, March 13). Lyons v. Bristol-Myers Squibb: Case No. 3:16cv414-MCR-GRJ. Retrieved from http://www.pacer.gov
  3. U.S. District Court, Northern District of Florida. (2018, March 13). Viechec v. Bristol-Myers Squibb; Case No. 3:16cv291-MCR-GRJ. Retrieved from http://www.pacer.gov
  4. U.S. District Court, Northern District of Florida. (2018, March 13). Lilly v. Bristol-Myers Squibb; Case No. 3:17cv186-MCR-GRJ. Retrieved from http://www.pacer.gov
  5. HarrisMartin Publishing. (2018, March 14). Fla. Federal Judge Selects Three Abilify MDL Cases for Trial. Retrieved from https://harrismartin.com/article/23294/fla-federal-judge-selects-three-abilify-mdl-cases-for-trial/
  6. U.S. Food and Drug Administration. (2017, December 31). Abilify. FDA Adverse Events Reporting Systems (FAERS) Public Dashboard. Retrieved from https://fis.fda.gov/sense/app/777e9f4d-0cf8-448e-8068-f564c31baa25
View All Sources
Call to speak with a legal expert
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(855) 715-9320

To contact Drugwatch Managing Editor Kevin Connolly, call (855) 839-9780.